Prof Michael Lind

Professor of Oncology, Head of Centre for Cancer

Professor Mike Lind is Foundation Professor of Oncology and has been involved in clinical oncology for 25 years, specialising in lung cancer.

Professor Lind qualified in 1981 from Guy’s Hospital. He undertook his training in oncology at Guy’s, the Christie Hospital, and Newcastle upon Tyne. In 1992 he was appointed senior lecturer in medical oncology, and to the foundation chair of oncology at the University of Hull in 1998.

His major area of interest is in thoracic malignancy. He chairs the NCIN lung site specific clinical reference group.

  • Wilkinson, P.M., et al., Epoetin alfa in platinum-treated ovarian cancer patients; results of a multinational, multicentre, randomised trial. Br J Cancer, 2006. 94(7): p. 947-54

  • Maraveyas, A., et al., Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study.  Br J Cancer, 2005. 92(5): p. 815-9

  • Baka, S., et al., Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer.  J Clin Oncol, 2005. 23(10): p. 2136-44

  • Azzabi, A., et al., Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.  Br J Cancer, 2005. 92(6): p. 1006-12

  • Leonard, R.C., et al., Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.  J Natl Cancer Inst, 2004. 96(14): p. 1076-83

  • Jodrell, D.I., et al., Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma.  Eur J Cancer, 2004. 40(12): p. 1872-7


Contact details
m.j.lind@hull.ac.uk
01482 461318

Update my profile